INTRODUCTION
Human immunodeficiency virus(HIV) causes an incurable
infection that leads ultimately to a terminal disease called
acquired immunodeficiency syndrome(AIDS).
Worldwide 25-30% of infected patients are women and
90% of them are 20-49year of age.
INCIDENCE OF HIV
• This disease alarmingly increasing both in the developed and
in developing countries.
The prevalence even in low risk population in America is
close to 1 in 1000.
• The seropositivity rate among US pregnant women is 1-2 per
1000.
• In most Asian countries the infection rate is less than 0.5%.
NACO’S 4-PRONGED PPTCT STRATEGY
Primary prevention of HIV among women of childbearing age
Preventing unintended pregnancies among women living with
HIV
Preventing HIV transmission from a woman living with HIV to
her infant
Providing appropriate treatment, care and support to women
living with HIV and their children and families
Maternal Risk Factors Influencing PTCT
High viral load
HIV subtype
Resistant strains
Advanced clinical stage
Concurrent STI
Recent infection
Viral, bacterial and parasitic (esp. malaria) placental
infection
Malnourishment
OBSTETRICAL RISK FACTORS INFLUENCING
PTCT
Uterine manipulation (amnio, external cephalic version)
Prolonged rupture of the membranes (>4 hours)
Placental Disruption (abruption, chorioamnionitis)
Intrapartum haemorrhage
Invasive foetal monitoring (scalp electrode/scalp blood
sampling)
Invasive delivery techniques: episiotomies, forceps, use of
metal cups for vacuum deliveries
INTERVENTIONS DURING PREGNANCY
Primary prevention of HIV in childbearing women
Provide HIV information to ALL pregnant women
Antenatal visits are opportunity for PPTCT
Prevention of unwanted pregnancy in HIV-positive women
Prevention of PTCT through ART (to mother and baby)
Safe obstetric practices
INTERVENTIONS DURING LABOUR AND
DELIVERY
Minimise vaginal examinations
Avoid prolonged labour
– Consider using oxytocin to shorten labour when appropriate
Avoid premature rupture of membranes
– Use Partogram to measure labour
– Avoid artificial rupture of membranes (unless necessary)
Avoid unnecessary trauma during delivery
– Use non-invasive foetal monitoring
– Avoid invasive procedures, such as using scalp electrodes or scalp sampling
– Avoid routine episiotomy
– Minimise the use of forceps or vacuum extractors
– Uterine manipulation - amnio, external cephalic version (ECV)
Do not use suction unless absolutely necessary
– If suction is a must, use either mechanical suction at <100 mm
Hg pressure or bulb suction, rather than mouth-operated suction
Clamp cord after it stops pulsating and after giving the
mother oxytocin.
For all infants:
– When head is delivered wipe infant’s face with gauze or cloth
– After infant is completely delivered, thoroughly wipe dry with
a towel and transfer to the mother
CONSIDERATIONS REGARDING MODE OF
DELIVERY
Caesarean section performed before the onset of labour or
membrane rupture has been associated with reduced HIV
Transmission from Mother to Child
The risk of elective Caesarean for PMTCT should be assessed
carefully in the context of factors such as:
– Risk of post-operative complications
– Safety of the blood supply
– Cost
In India, normal vaginal delivery is recommended unless the
woman has obstetric reasons (like foetal distress, obstructed
labour, etc) for a C-section
Use of ART can reduce risk of PTCT better and with less risk
than a C-section
INTERVENTIONS DURING INFANCY
Observe for signs and symptoms of HIV infection
All HIV exposed infants should receive cotrimoxazole at 4-6
weeks of age.
Follow standard immunization schedule
Routine well baby visits
DNA PCR
18-month visit for HIV testing
INTERVENTIONS FOR SAFER INFANT
FEEDING
Exclusive breastfeeding
Support good breast health and hygiene
Replacement feeding – if Affordable, Feasible, Acceptable,
Sustainable and Safe (AFASS)
Avoiding addition of supplements or mixed feeding which
enhance HIV transmission Discussions with mothers about the
above must consider personal, familial and cultural concerns
ARV prophylaxis: Short-term use of antiretroviral drugs to
reduce HIV transmission from mother-to- infant.
ARV therapy: Long-term use of antiretroviral drugs to treat
maternal HIV and for PPTCT.
ARVs during pregnancy decrease the HIV viral load in the
mother’s blood, thus lowering the chance of her infant to get
exposed to the virus.
ANTIREROVIRAL PROPHYLAXIS
MONOTHERAPY
Nevirapine (NACO Guidelines)
– Mother - Single dose NVP 200mg onset of labour
– Baby - Syrup NVP 2mg/kg within 72 hours of delivery
Zidovudine syrup- infant less than 2.5kg/ 15mg/ twice day.
Revised NACO Guidelines will be in place shortly
ARV PROPHYLAXIS DURING LABOUR &
DELIVERY FOR HIV-INFECTED WOMEN
Administer ARV therapy or ARV prophylaxis during labour
according to national guidelines to reduce maternal viral load
and provide protection to the infant
Avoid repeat dosing of single-dose NEVIRAPINE (e.g., in
the case of false labour), as this can cause viral resistance
– Ensure that a woman is in true labour before administering a single-
dose of NVP
– Document NVP administration clearly on a patient’s Partogram or
medical record to avoid accidental repeat dosing PPTCT